Integrated GlycoProteome Analyzer (I-GPA) for Automated Identification and Quantitation of Site-Specific N-Glycosylation

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Park, Gun Wook ^a,b   Kim, Jin Young ^a   Hwang, Heeyoun ^a   Lee, Ju Yeon ^a   Ahn, Young Hee ^c   Lee, Hyun Kyoung ^a,b   Ji, Eun Sun ^a,d   Kim, Kwang Hoe ^a,b   Jeong, Hoi Keun ^a,b   Yun, Ki Na ^a,e   Kim, Yong Sam ^f   Ko, Jeong Heon ^f   An, Hyun Joo ^b   Kim, Jae Han ^b   Paik, Young Ki ^g   Yoo, Jong Shin ^a,b  

^a Korea Basic Science Institute (KBSI)   (South Korea)

^b Chungnam National University   (South Korea)

^c Chongju University   (South Korea)

^d Hannam University   (South Korea)

^e Sogang University   (South Korea)

^f Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^g Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPEPTIDE; GLYCOPROTEIN; PLASMA PROTEIN; PROTEOME;

ALGORITHM; BLOOD; CHEMISTRY; DEVICES; GLYCOSYLATION; HUMAN; LABORATORY AUTOMATION; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PROCEDURES; PROTEOMICS; REPRODUCIBILITY;

ALGORITHMS; AUTOMATION, LABORATORY; BLOOD PROTEINS; CARCINOMA, HEPATOCELLULAR; GLYCOPEPTIDES; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; LIVER NEOPLASMS; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS;

EID: 84958554964     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep21175     Document Type: Article

References (43)

1. Barrabes, S. et al. Glycosylation of serum ribonuclease 1 indicates a major endothelial origin and reveals an increase in core fucosylation in pancreatic cancer. Glycobiology 17, 388-400 (2007).
2. Hwang, H. et al. Glycoproteomics in neurodegenerative diseases. Mass Spectrom. Revs. 29, 79-125 (2010).
3. Ahn, Y. H., Kim, J. Y., Yoo, J. S. Quantitative mass spectrometric analysis of glycoproteins combined with enrichment methods. Mass Spectrom. Revs. 34, 148-165 (2015).
4. Kirmiz, C. et al. A serum glycomics approach to breast cancer biomarkers. Mol. Cell. Proteomics 6, 43-55 (2007).
5. Toyama, A. et al. Quantitative structural characterization of local N-glycan microheterogeneity in therapeutic antibodies by energyresolved oxonium ion monitoring. Anal. Chem. 84, 9655-9662 (2012).
6. Chen, R. et al. Development of glycoprotein capture-based label-free method for the high-throughput screening of differential glycoproteins in hepatocellular carcinoma. Mol. Cell. Proteomics 10, M110 006445 (2011).
7. Ishihara, T. et al. Development of quantitative plasma N-glycoproteomics using label-free 2-D LC-MALDI MS and its applicability for biomarker discovery in hepatocellular carcinoma. J. Proteom. 74, 2159-2168 (2011).
8. Zielinska, D. F., Gnad, F., Wisniewski, J. R., Mann, M. Precision mapping of an in vivo N-glycoproteome reveals rigid topological and sequence constraints. Cell 141, 897-907 (2010).
9. Yang, G. et al. Selective isolation and analysis of glycoprotein fractions and their glycomes from hepatocellular carcinoma sera. Proteomics 13, 1481-1498 (2013).
10. Ahn, Y. H. et al. A lectin-coupled, targeted proteomic mass spectrometry (MRM MS) platform for identification of multiple liver cancer biomarkers in human plasma. J. Proteom. 75, 5507-5515 (2012).
11. Taylor, A. D. et al. Towards an integrated proteomic and glycomic approach to finding cancer biomarkers. Genome Medicine 1, 57 (2009).
12. Liu, Y. et al. Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations. J. Proteome. Res. 9, 798-805 (2010).
13. Doerr, A. Glycoproteomics. Nat. Methods 9, 36 (2012).
14. Wada, Y., Tajiri, M., Yoshida, S. Hydrophilic affinity isolation and MALDI multiple-stage tandem mass spectrometry of glycopeptides for glycoproteomics. Anal. Chem. 76, 6560-6565 (2004).
15. Rebecchi, K. R., Wenke, J. L., Go, E. P., Desaire, H. Label-free quantitation: a new glycoproteomics approach. J. Am. Soc. Mass Spectrom. 20, 1048-1059 (2009).
16. Pompach, P. et al. Site-specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma. Mol. Cell. Proteomics 12, 1281-1293 (2013).
17. Trinidad, J. C., Schoepfer, R., Burlingame, A. L., Medzihradszky, K. F. N-and O-glycosylation in the murine synaptosome. Mol. Cell. Proteomics 12, 3474-3488 (2013).
18. Parker, B. L. et al. Site-specific glycan-peptide analysis for determination of N-glycoproteome heterogeneity. J. Proteome. Res. 12, 5791-5800 (2013).
19. Mayampurath, A. et al. Computational framework for identification of intact glycopeptides in complex samples. Anal. Chem. 86, 453-463 (2014).
20. Strum, J. S. et al. Automated assignments of N-and O-site specific glycosylation with extensive glycan heterogeneity of glycoprotein mixtures. Anal. Chem. 85, 5666-5675 (2013).
21. Wu, S. W. et al. Sweet-Heart-an integrated suite of enabling computational tools for automated MS2/MS3 sequencing and identification of glycopeptides. J. Proteom. 84, 1-16 (2013).
22. Chandler, K. B., Pompach, P., Goldman, R., Edwards, N. Exploring site-specific N-glycosylation microheterogeneity of haptoglobin using glycopeptide CID tandem mass spectra and glycan database search. J. Proteome. Res. 12, 3652-3666 (2013).
23. Bern, M., Kil, Y. J., Becker, C. Byonic: advanced peptide and protein identification software. Curr. Protoc. Bioinformatics. Chapter 13, Unit13 20 (2012).
24. Lynn, K. S. et al. MAGIC: an automated N-linked glycoprotein identification tool using a Y1-ion pattern matching algorithm and in silico MS(2) approach. Anal. Chem. 87, 2466-2473 (2015).
25. Wu, S. W., Pu, T. H., Viner, R., Khoo, K. H. Novel LC-MS2 product dependent parallel data acquisition function and data analysis workflow for sequencing and identification of intact glycopeptides. Anal. Chem. 86, 5478-5486 (2014).
26. Paik Y. K. et al. The Chromosome-Centric Human Proteome Project for cataloging proteins encoded in the genome. Nat. Biotechnol. 30, 221-3 (2012).
27. Kronewitter, S. R. et al. The development of retrosynthetic glycan libraries to profile and classify the human serum N-linked glycome. Proteomics 9, 2986-2994 (2009).
28. Ozohanics, O. et al. High-performance liquid chromatography coupled to mass spectrometry methodology for analyzing sitespecific N-glycosylation patterns. J. Chromatogr. A 1259, 200-212 (2012).
29. Farrah, T. et al. A high-confidence human plasma proteome reference set with estimated concentrations in Peptide Atlas. Mol. Cell. Proteomics 10, M110 006353 (2011).
30. Hart-Smith, G., Raftery, M. J. Detection and characterization of low abundance glycopeptides via higher-energy C-trap dissociation and orbitrap mass analysis. J. Am. Soc. Mass Spectrom. 23, 124-140 (2012).
31. Tessitore, A. et al. Serum biomarkers identification by mass spectrometry in high-mortality tumors. Int. J. Proteomics 2013, 125858 (2013).
32. Sukata, T. et al. alpha(2)-Macroglobulin: a novel cytochemical marker characterizing preneoplastic and neoplastic rat liver lesions negative for hitherto established cytochemical markers. Am. J. Pathology 165, 1479-1488 (2004).
33. Lukanova, A. et al. Prediagnostic plasma testosterone, sex hormone-binding globulin, IGF-I and hepatocellular carcinoma: etiological factors or risk markers? Int. J. Cancer 134, 164-173 (2014).
34. Qin, X., Gao, B. The complement system in liver diseases. Cell. Mol. Immunol. 3, 333-340 (2006).
35. Poon, T. C. et al. Application of classification tree and neural network algorithms to the identification of serological liver marker profiles for the diagnosis of hepatocellular carcinoma. Oncology 61, 275-283 (2001).
36. Jing, Y. et al. SERPINA5 inhibits tumor cell migration by modulating the fibronectin-integrin beta1 signaling pathway in hepatocellular carcinoma. Mol. Oncology 8, 366-377 (2014).
37. Akhavan, A. et al. Loss of cell-surface laminin anchoring promotes tumor growth and is associated with poor clinical outcomes. Cancer Res. 72, 2578-2588 (2012).
38. Nafee, A. M. et al. Clinical significance of serum clusterin as a biomarker for evaluating diagnosis and metastasis potential of viralrelated hepatocellular carcinoma. Clinical Biochem. 45, 1070-1074 (2012).
39. Asao, T. et al. Development of a novel system for mass spectrometric analysis of cancer-associated fucosylation in plasma alpha1-acid glycoprotein. BioMed Res. International 2013, 834790 (2013).
40. Kobayashi, S. et al. Clinical utility of serum fucosylated hemopexin in Japanese patients with hepatocellular carcinoma. Hepatology Res. 42, 1187-1195 (2012).
41. Blomme, B., Van Steenkiste, C., Callewaert, N., Van Vlierberghe, H. Alteration of protein glycosylation in liver diseases. J. Hepatology 50, 592-603 (2009).
42. Mayampurath, A. et al. Label-Free Glycopeptide Quantification for Biomarker Discovery in Human Sera. J. Proteome. Res. 13, 4821-4832 (2014).
43. Huffman, J. E. et al. Comparative Performance of Four Methods for High-throughput Glycosylation Analysis of Immunoglobulin G in Genetic and Epidemiological Research. Mol. Cell. Proteomics 13, 1598-1610 (2014).